Comparison of frequency of insulin resistance after coronary stenting in patients with type 2 diabetes mellitus with versus without coronary restenosis

被引:18
作者
Feola, M
Ribichini, F
Ferrero, V
Procopio, M
Magro, G
Vado, A
Borretta, G
Boccuzzi, G
Vassanelli, C
Uslenghi, E
机构
[1] Osped Santa Croce & Carle, Dept Cardiovasc Dis, I-12100 Cuneo, Italy
[2] Osped Santa Croce & Carle, Div Endocrinol, I-12100 Cuneo, Italy
[3] Univ Piemonte Orientale, Osped Maggiore Carita, Div Cardiol, Novara, Italy
关键词
D O I
10.1016/j.amjcard.2004.05.066
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The large incidence of restenosis after coronary angioplasty in diabetic patients renders this procedure less effective than in nondiabetics, and insulin resistance could be a relevant cause of restenosis in such patients. This study assessed insulin resistance and biologic markers of metabolic control in type 2 diabetic patients treated with stented angioplasty. Seventy-four patients were studied prospectively. Biochemical determinations, insulin tolerance test results, and the rate constant for plasma glucose disappearance (K-itt%) were obtained. The angiographic outcome of angioplasty was assessed by quantitative coronary analysis at baseline and at 6 months in 64 patients (86%). Patients with restenosis had smaller minimum luminal diameters after stenting (2.8 +/- 0.5 vs 3.04 +/- 0.5 mm, p = 0.05), were more often hypertensive (97% vs 79%, p = 0.02) and treated with angiotensin-converting enzyme inhibitors (53% vs 23%, p = 0.02), and had smaller K-itt% (2.9 +/- 1.6%/min vs 3.7 +/- 1.4%/min, p = 0.04) and larger titers of growth hormone (1.36 +/- 1.5 vs 0.68 +/- 0.6 ng/ml, p = 0.02). (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:777 / 780
页数:4
相关论文
共 13 条
[1]   Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease - The bypass angioplasty revascularization investigation (BARI) [J].
Alderman, E ;
Bourassa, M ;
Brooks, MM ;
Califf, R ;
Chaitman, B ;
Detre, K ;
Faxon, DP ;
Feit, F ;
Frye, RL ;
Hardison, RM ;
Holmes, D ;
Holubkov, R ;
Kouchoukos, N ;
Krone, R ;
Rogers, W ;
Rosen, AD ;
Schaff, H ;
Schwartz, L ;
Siewers, AS ;
Sopko, G ;
SuttonTyrrell, K ;
Whitlow, P .
CIRCULATION, 1997, 96 (06) :1761-1769
[2]   ESTIMATES OF INVIVO INSULIN ACTION IN MAN - COMPARISON OF INSULIN TOLERANCE-TESTS WITH EUGLYCEMIC AND HYPERGLYCEMIC GLUCOSE CLAMP STUDIES [J].
BONORA, E ;
MOGHETTI, P ;
ZANCANARO, C ;
CIGOLINI, M ;
QUERENA, M ;
CACCIATORI, V ;
CORGNATI, A ;
MUGGEO, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1989, 68 (02) :374-378
[3]   Coronary revascularization in diabetic patients - A comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI) [J].
Detre, KM ;
Guo, P ;
Holubkov, R ;
Califf, RM ;
Sopko, G ;
Bach, R ;
Brooks, MM ;
Bourassa, MG ;
Shemin, RJ ;
Rosen, AD ;
Krone, RJ ;
Frye, RL ;
Feit, F .
CIRCULATION, 1999, 99 (05) :633-640
[4]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[5]  
INCHIOSTRO S, 1994, DIABETOLOGIA, V37, P597, DOI 10.1007/s001250050153
[6]   The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? [J].
Janssen, JAMJL ;
Lamberts, SWJ .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (04) :467-477
[7]   Midterm angiographic outcome of single-vessel intracoronary stent placement in diabetic versus nondiabetic patients: A matched comparative study [J].
Lau, KW ;
Ding, ZP ;
Johan, A ;
Lim, YL .
AMERICAN HEART JOURNAL, 1998, 136 (01) :150-155
[8]   Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I) [J].
Levine, GN ;
Jacobs, AK ;
Keeler, GP ;
Whitlow, PL ;
Berdan, LG ;
Leya, F ;
Topol, EJ ;
Califf, RM .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (06) :748-755
[9]   IGF-I/IGF-Binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms [J].
O'Connell, T ;
Clemmons, DR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09) :4356-4360
[10]   Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? [J].
O'Keefe, JH ;
Wetzel, M ;
Moe, RR ;
Brosnahan, K ;
Lavie, CJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (01) :1-8